The intrarenal renin-angiotensin system and diabetic nephropathy

被引:172
作者
Carey, RM [1 ]
Siragy, HM [1 ]
机构
[1] Univ Virginia, Sch Med, Div Endocrinol & Metab, Dept Med,Hlth Syst, Charlottesville, VA 22908 USA
关键词
HUMAN MESANGIAL CELLS; II RECEPTOR BLOCKADE; AT(2) RECEPTOR; CONVERTING ENZYME; TYPE-2; RECEPTOR; MICE LACKING; NITRIC-OXIDE; EXPRESSION; INSULIN; MELLITUS;
D O I
10.1016/S1043-2760(03)00111-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The renin-angiotensin system (RAS) is a coordinated cascade of proteins and peptide hormones, the principal effector of which is angiotensin II (ANG II). Evidence now indicates that the kidney regulates its function via a self-contained RAS in a paracrine fashion. In diabetic nephropathy, the intrarenal generation of ANG II is increased, in spite of suppression of the systemic RAS. This increase can contribute to the progression of diabetic nephropathy via several hemodynamic, tubular and growth-promoting actions. ANG II induces insulin resistance. ANG II type-1 (ATE) and type-2 (AT(2)) receptors are downregulated in chronic diabetes, but decreased AT(2) receptor expression might contribute to early diabetic nephropathy by reducing AT(2) receptormediated beneficial actions that are counter-regulatory to those of the AT(1) receptor. AT(2) receptor stimulation might account for part of the renal protection seen with AT(1) receptor blockade. A rat model of accelerated diabetic nephropathy is the (mREN-2) 27 renin transgenic rat treated with streptozotocin in which both the intrarenal and extrarenal RAS is activated.
引用
收藏
页码:274 / 281
页数:8
相关论文
共 81 条
  • [21] Mice lacking endothelial ACE - Normal blood pressure with elevated angiotensin
    Cole, JM
    Khokhlova, N
    Sutliff, RL
    Adams, JW
    Disher, KM
    Zhao, H
    Capecchi, MR
    Corvol, P
    Bernstein, KE
    [J]. HYPERTENSION, 2003, 41 (02) : 313 - 321
  • [22] Pathogenesis, prevention, and treatment of diabetic nephropathy
    Cooper, ME
    [J]. LANCET, 1998, 352 (9123) : 213 - 219
  • [23] Angiotensin-converting enzyme 2 is an essential regulator of heart function
    Crackower, MA
    Sarao, R
    Oudit, GY
    Yagil, C
    Kozieradzki, I
    Scanga, SE
    Oliveira-dos-Santos, AJ
    da Costa, J
    Zhang, LY
    Pei, Y
    Scholey, J
    Ferrario, CM
    Manoukian, AS
    Chappell, MC
    Backx, PH
    Yagil, Y
    Penninger, JM
    [J]. NATURE, 2002, 417 (6891) : 822 - 828
  • [24] Angiotensin AT2 receptor degradation is prevented by ligand occupation
    Csikós, T
    Balmforth, AJ
    Grojec, M
    Gohlke, P
    Culman, J
    Unger, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (01) : 142 - 147
  • [25] A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
    Donoghue, M
    Hsieh, F
    Baronas, E
    Godbout, K
    Gosselin, M
    Stagliano, N
    Donovan, M
    Woolf, B
    Robison, K
    Jeyaseelan, R
    Breitbart, RE
    Acton, S
    [J]. CIRCULATION RESEARCH, 2000, 87 (05) : E1 - E9
  • [26] Kinins, receptors, kininases and inhibitors -: Where did they lead us?
    Erdös, EG
    Marcic, BM
    [J]. BIOLOGICAL CHEMISTRY, 2001, 382 (01) : 43 - 47
  • [27] Counterregulatory actions of angiotensin-(1-7)
    Ferrario, CM
    Chappell, MC
    Tallant, EA
    Brosnihan, KB
    Diz, DI
    [J]. HYPERTENSION, 1997, 30 (03) : 535 - 541
  • [28] Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels - A potential role for serine phosphorylation in insulin/angiotensin II crosstalk
    Folli, F
    Kahn, CR
    Hansen, H
    Bouchie, JL
    Feener, EP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (09) : 2158 - 2169
  • [29] Gerstein HC, 2000, LANCET, V355, P253
  • [30] Inhibition of pressure natriuresis in mice lacking the AT2 receptor
    Gross, V
    Schunck, WH
    Honeck, H
    Milia, AF
    Kärgel, E
    Walther, T
    Bader, M
    Inagami, T
    Schneider, W
    Luft, FC
    [J]. KIDNEY INTERNATIONAL, 2000, 57 (01) : 191 - 202